# Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

> **NCT07383441** · PHASE3 · NOT_YET_RECRUITING · sponsor: **SWOG Cancer Research Network** · enrollment: 718 (estimated)

## Conditions studied

- Advanced Clear Cell Renal Cell Carcinoma
- Metastatic Clear Cell Renal Cell Carcinoma
- Stage III Renal Cell Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8

## Interventions

- **DRUG:** Axitinib
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Scan
- **DRUG:** Cabozantinib
- **DRUG:** Clostridium butyricum CBM 588 Probiotic Strain
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Ipilimumab
- **DRUG:** Lenvatinib
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Nivolumab
- **DRUG:** Nivolumab and Recombinant Human Hyaluronidase
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Placebo Administration

## Key facts

- **NCT ID:** NCT07383441
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-10
- **Primary completion:** 2033-01-31
- **Final completion:** 2034-01-31
- **Target enrollment:** 718 (ESTIMATED)
- **Last updated:** 2026-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07383441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07383441, "Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07383441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*